Polymyositis

6 trials 5 recruiting MedDRA PT
6 Registered trials
5 Recruiting
5 Unique sponsors
6 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Monoclonal antibody 1 substance
JAK inhibitor 1 substance
Phase III: 3 Phase II: 3

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

3 trials
  • AstraZeneca AB Commercial
    ANIFROLUMAB
    2023-504022-19-01 13 countries 2024 n=84 Orphan
    Recruiting
  • Pfizer Inc. Commercial
    DAZUKIBART; HUMANISED IGG1K MONOCLONAL ANTIBODY AGAINST INTERFERON BETA
    2022-502739-20-00 10 countries 2023 n=79 Orphan
    Recruiting
  • Pfizer Inc. Commercial
    DAZUKIBART
    2024-514648-10-00 6 countries 2025 n=23 Orphan
    Recruiting

Phase II

3 trials
  • Merck Healthcare KGaA Commercial
    ENPATORAN
    2022-501351-82-00 6 countries 2023 n=15
    Ended
  • Medical University Of Vienna Academic
    UPADACITINIB
    2024-513681-19-00 1 country 2025 n=10
    Recruiting
  • Universitaetsklinikum Schleswig-Holstein AöR Academic
    ALDESLEUKIN
    2023-510297-14-00 1 country 2024 n=112 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 2 Phase III 2
Merck Healthcare KGaA Commercial 1 Phase II 0
AstraZeneca AB Commercial 1 Phase III 1
Medical University Of Vienna Academic 1 Phase II 1
Universitaetsklinikum Schleswig-Holstein AöR Academic 1 Phase II 1
New trials by year
2023
2
2024
2
2025
2
← All indication landscapes